Safety and efficacy of nivolumab in metastatic renal cell carcinoma (mRCC): Results from the NIVOREN GETUG-AFU 26 study.

被引：9
|
作者：
Albiges, Laurence
Negrier, Sylvie
Dalban, Cecile
Gravis, Gwenaelle
Chevreau, Christine
Oudard, Stephane
Laguerre, Brigitte
Barthelemy, Philippe
Borchiellini, Delphine
Gross-Goupil, Marine
Geoffrois, Lionnel
Brihoum, Meryem
Escudier, Bernard
机构：
[1] Univ Paris Sud, Gustave Roussy Inst Oncol, Villejuif, France
[2] Ctr Leon Berard, Lyon, France
[3] Inst Paoli Calmettes, Marseille, France
[4] IUCT Oncopole Inst Claudius Regaud, Toulouse, France
[5] AP HP, Hop Europeen Georges Pompidou, Paris, France
[6] Ctr Eugene Marquis, Rennes, France
[7] Hopitaux Univ Strasbourg, Strasbourg, France
[8] Ctr Antoine Lacassagne, Nice, France
[9] Ctr Hosp Univ St Andre, Bordeaux, France
[10] Inst Cancerol Lorraine, Vandoeuvre Les Nancy, France
[11] UNICANCER, Paris, France
[12] Gustave Roussy Canc Campus, Villejuif, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 06期
关键词：
D O I：
10.1200/JCO.2018.36.6_suppl.577
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
577
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Efficacy and safety of everolimus in elderly patients (pts) with metastatic renal cell carcinoma (mRCC)
    Osanto, S.
    Hutson, T. E.
    Calvo, E.
    Escudier, B. J.
    Oudard, S.
    Porta, C.
    Bracarda, S.
    Grunwald, V.
    Ravaud, A.
    Motzer, R. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [42] Safety and preliminary activity of hydroxychloroquine and aldesleukin in metastatic renal cell carcinoma (mRCC): A cytokine working group study.
    Appleman, Leonard Joseph
    Logan, Theodore F.
    Normolle, Daniel Paul
    Ernstoff, Marc S.
    Parikh, Rahul Atul
    McDermott, David F.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [43] Phase I study of nivolumab in combination with ipilimumab (IPI) in metastatic renal cell carcinoma (mRCC)
    Hammers, H.
    Plimack, E. R.
    Infante, J. R.
    Ernstoff, M. S.
    Rini, B.
    Mcdermott, D. F.
    Razak, A.
    Pal, S. K.
    Voss, M. H.
    Sharma, P.
    Kollmannsberger, C.
    Heng, D. Y. C.
    Spratlin, J.
    Shen, Y.
    Kurland, J. F.
    Gagnier, P.
    Amin, A.
    BJU INTERNATIONAL, 2014, 114 : 8 - 8
  • [44] Tivozanib combined with nivolumab: Phase Ib/II study in metastatic renal cell carcinoma (mRCC).
    Escudier, Bernard
    Barthelemy, Philippe
    Ravaud, Alain
    Negrier, Sylvie
    Needle, Michael N.
    Albiges, Laurence
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [45] Activity and safety of cabozantinib (cabo) in brain metastases (BM) from metastatic renal cell carcinoma (mRCC): An international multicenter study.
    Hirsch, Laure
    Chanza, Nieves Martinez
    Farah, Subrina
    Flippot, Ronan
    Rathi, Nityam
    Collier, Katharine
    de Velasco, Guillermo
    Seront, Emmanuel
    Beuselinck, Benoit
    Xu Wenxin
    Bowman, Isaac Alexander
    Lam, Elaine Tat
    Dzimitrowicz, Hannah Elizabeth
    Zakharia, Yousef
    McKay, Rana R.
    Bilen, Mehmet Asim
    Albiges, Laurence
    Xie Wanling
    Harshman, Lauren C.
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [46] A prospective phase II study of gemcitabine plus platinum in combination with bevacizumab for metastatic renal medullary and collecting duct carcinoma (GETUG-AFU 24, BEVABEL trial)
    Thibault, C.
    Elaidi, R. T.
    Flechon, A.
    Albiges, L.
    Joly, C.
    Barthelemy, P.
    Goupil, M. Gross
    Chevreau, C. M.
    Joly, F.
    Rolland, F.
    Laguerre, B.
    Gravis, G.
    Brihoum, M.
    Timsit, M-O.
    Pecuchet, N.
    Allory, Y.
    Oudard, S.
    ANNALS OF ONCOLOGY, 2020, 31 : S568 - S568
  • [47] The impact of kidney function on the efficacy and safety of pazopanib in metastatic renal cell carcinoma (mRCC) patients: CORE-UR0-01 study.
    Vitale, Maria Giuseppa
    Masini, Cristina
    Procopio, Giuseppe
    De Giorgi, Ugo
    Buti, Sebastiano
    Rossetti, Sabrina
    Iacovelli, Roberto
    Mucciarini, Claudia
    Cosmai, Laura
    Vignani, Francesca
    Prati, Giuseppe
    Scagliarini, Sarah
    Berselli, Annalisa
    Pinto, Carmine
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [48] Updated results from a phase I study of nivolumab (Nivo) in combination with ipilimumab (Ipi) in metastatic renal cell carcinoma (mRCC): The CheckMate 016 study
    Hammers, H.
    Plimack, E. R.
    Infante, J. R.
    Rini, B. I.
    McDermott, D.
    Lewis, L.
    Voss, M. H.
    Sharma, P.
    Pal, S. K.
    Razak, A.
    Kollmannsberger, C. K.
    Heng, D.
    Spratlin, J.
    McHenry, B.
    Gagnier, P.
    Amin, A.
    ANNALS OF ONCOLOGY, 2016, 27
  • [49] Updated survival results from a randomized, dose-ranging phase II study of nivolumab (NIVO) in metastatic renal cell carcinoma (mRCC).
    Plimack, Elizabeth R.
    Hammers, Hans J.
    Rini, Brian I.
    McDermott, David F.
    Redman, Bruce
    Kuzel, Timothy
    Harrison, Michael Roger
    Vaishampayan, Ulka N.
    Drabkin, Harry A.
    George, Saby
    Logan, Theodore F.
    Margolin, Kim Allyson
    Xu, Li-an
    Waxman, Ian
    Motzer, Robert
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [50] UPDATED SURVIVAL RESULTS FROM A RANDOMIZED, DOSE-RANGING PHASE II STUDY OF NIVOLUMAB (NIVO) IN METASTATIC RENAL CELL CARCINOMA (MRCC)
    Plimack, Elizabeth R.
    Hammers, Hans J.
    Rini, Brian I.
    McDermott, David F.
    Redman, Bruce G.
    Kuzel, Timothy M.
    Harrison, Michael R.
    Vaishampayan, Ulka N.
    Drabkin, Harry A.
    George, Saby
    Logan, Theodore F.
    Margolin, Kim A.
    Xu, Li-An
    Waxman, Ian M.
    Motzer, Robert J.
    Asia-Pacific Journal of Clinical Oncology, 2015, 11 : 129 - 129
12345